Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director · CEO, President, Chairman · 10% owner | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,164,600 |
Reported balance
After 2026-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 400 · Balance 2,164,600 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,825 |
Reported balance
After 2026-06-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-01 · Sale · Disposed 775 · Balance 2,163,825 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,424 |
Reported balance
After 2026-06-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-06-01 · Sale · Disposed 401 · Balance 2,163,424 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,162,500 |
Reported balance
After 2026-06-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-06-01 · Sale · Disposed 924 · Balance 2,162,500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Roger E. Susi Revocable Trust | 162,950 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 162,950 |
| Common StockSEC Table I · non-derivative | IndirectBy Matthew Susi 2008 Dynasty Trust | 2,062,500 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,062,500 F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2022 Filed Mar 17, 2022 11:39 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $46.65 | $466,547.00 |
DisclosureSEC source: 0000898432-22-000222 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 692,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.67 to $48.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 23:26 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.04 | $470,353.00 |
DisclosureSEC source: 0000898432-22-000219 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 702,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.17 to $49.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $49.26 | $492,554.00 |
DisclosureSEC source: 0000898432-22-000210 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 712,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.32 to $50.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 00:29 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.00 | $469,959.00 |
DisclosureSEC source: 0000898432-22-000198 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 722,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.54 to $47.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:10 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.15 | $471,506.00 |
DisclosureSEC source: 0000898432-22-000121 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 732,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.13 to $48.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 21:09 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.44 | $474,434.00 |
DisclosureSEC source: 0000898432-22-000079 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 742,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.10 to $48.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:43 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $39.44 | $394,417.00 |
DisclosureSEC source: 0000898432-22-000076 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 752,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.07 to $40.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 21:09 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $37.06 | $370,559.00 |
DisclosureSEC source: 0000898432-22-000065 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 762,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.93 to $39.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 18, 2022 23:54 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $41.21 | $412,056.00 |
DisclosureSEC source: 0000898432-22-000035 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 772,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.42 to $43.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:06 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $44.54 | $445,379.00 |
DisclosureSEC source: 0000898432-22-000034 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 782,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.59 to $45.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 22:39 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $48.56 | $485,629.00 |
DisclosureSEC source: 0000898432-22-000015 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 792,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.26 to $49.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:35 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.11 | $471,073.00 |
DisclosureSEC source: 0000898432-21-000946 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 826,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.78 to $47.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 27, 2021 Filed Jan 4, 2022 22:37 UTC | IRADIMED CORP IRMD · Entity 4896 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000014 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 802,950 Read SEC document |
| December 27, 2021 Filed Jan 4, 2022 22:37 UTC | IRADIMED CORP IRMD · Entity 4896 | GiftCommon Stock | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000014 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 803,450 Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 21:41 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $44.38 | $443,800.00 |
DisclosureSEC source: 0000898432-21-000936 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 836,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.84 to $44.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:07 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,500 | $44.12 | $154,437.15 |
DisclosureSEC source: 0000898432-21-000920 · form4.xml · nonDerivative · entry 3 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 846,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.06 to $45.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:07 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,500 | $44.00 | $66,000.00 |
DisclosureSEC source: 0000898432-21-000920 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 849,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 21:07 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $44.25 | $221,250.00 |
DisclosureSEC source: 0000898432-21-000920 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 851,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:19 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $44.37 | $443,706.00 |
DisclosureSEC source: 0000898432-21-000757 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 856,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.00 to $45.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 23:43 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $44.96 | $449,570.00 |
DisclosureSEC source: 0000898432-21-000744 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 866,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.80 to $46.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 23:01 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $40.32 | $403,150.00 |
DisclosureSEC source: 0000898432-21-000739 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 876,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.53 to $41.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:07 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $34.47 | $172,332.50 |
DisclosureSEC source: 0000898432-21-000655 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 886,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.05 to $35.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:07 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $35.17 | $175,868.50 |
DisclosureSEC source: 0000898432-21-000655 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 891,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.87 to $35.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 01:46 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.45 | $167,245.50 |
DisclosureSEC source: 0000898432-21-000640 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 896,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.32 to $33.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 01:46 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.70 | $168,489.00 |
DisclosureSEC source: 0000898432-21-000640 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 901,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.33 to $34.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 21:52 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.59 | $167,974.00 |
DisclosureSEC source: 0000898432-21-000612 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 906,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021 F3 · price: This transaction was executed in multiple trades at prices ranging from $33.29 to $34.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:52 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.74 | $168,712.00 |
DisclosureSEC source: 0000898432-21-000612 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 911,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021 F2 · price: This transaction was executed in multiple trades at prices ranging from $33.21 to $34.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 20, 2021 Filed Aug 20, 2021 20:51 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.33 | $166,653.00 |
DisclosureSEC source: 0001602030-21-000002 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 916,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.00 to $33.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:51 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.26 | $166,319.50 |
DisclosureSEC source: 0001602030-21-000002 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 921,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.01 to $33.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:43 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $35.18 | $175,914.00 |
DisclosureSEC source: 0000898432-21-000600 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 926,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.87 to 35.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:43 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $35.47 | $177,337.50 |
DisclosureSEC source: 0000898432-21-000600 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 931,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.11 to 36.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 04, 2021 Filed Aug 4, 2021 21:29 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.81 | $169,041.00 |
DisclosureSEC source: 0000898432-21-000594 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 936,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.67 to $34.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:29 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.93 | $169,657.50 |
DisclosureSEC source: 0000898432-21-000594 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 941,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.46 to $34.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 15:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $34.43 | $172,160.00 |
DisclosureSEC source: 0000898432-21-000586 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 946,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.66 to $34.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 15:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $34.68 | $173,390.00 |
DisclosureSEC source: 0000898432-21-000586 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 951,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.39 to $35.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 22:06 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $34.03 | $170,150.00 |
DisclosureSEC source: 0000898432-21-000579 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 956,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.24 to $35.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 22:06 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $33.87 | $169,350.00 |
DisclosureSEC source: 0000898432-21-000579 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 961,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.39 to $34.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 16, 2021 Filed Jul 19, 2021 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 19,000 | $33.78 | $641,820.00 |
DisclosureSEC source: 0000898432-21-000577 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 966,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.90 to $35.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 09, 2021 Filed Jul 9, 2021 22:36 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,000 | $30.36 | $30,355.00 |
DisclosureSEC source: 0000898432-21-000565 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021 F2 · price: The shares for this transaction were all executed at $30.355. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 22:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $28.18 | $140,892.50 |
DisclosureSEC source: 0000898432-21-000510 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $28.00 to $28.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 22:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $28.38 | $141,890.50 |
DisclosureSEC source: 0000898432-21-000510 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.25 to $28.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 23, 2021 Filed Jun 23, 2021 23:13 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,907 | $27.82 | $108,702.12 |
DisclosureSEC source: 0000898432-21-000493 · form4.xml · nonDerivative · entry 3 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $27.51 to $28.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 23:13 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $27.77 | $138,865.00 |
DisclosureSEC source: 0000898432-21-000493 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 23:13 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,093 | $28.48 | $31,127.55 |
DisclosureSEC source: 0000898432-21-000493 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.40 to $28.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 22:34 UTC | IRADIMED CORP IRMD · Entity 4896 | GiftCommon Stock | 30,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000690 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO, and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 985,050 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 17, 2020 Filed Feb 20, 2020 21:02 UTC | IRADIMED CORP IRMD · Entity 4896 | GiftCommon Stock | 25,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-20-000117 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · Chief Tech. Officer, Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 1,015,550 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 20:40 UTC | IRADIMED CORP IRMD · Entity 4896 | GiftCommon Stock | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-001161 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · Chief Technology Offr, Chmn · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 1,040,800 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | PurchaseCommon Stock | 1,000 | $13.85 | $13,850.00 |
DisclosureSEC source: 0000898432-18-000358 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, President, Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 22:56 UTC | IRADIMED CORP IRMD · Entity 4896 | PurchaseCommon Stock | 5,000 | $8.65 | $43,250.00 |
DisclosureSEC source: 0001140361-17-005881 · doc1.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, President, Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 22:56 UTC | IRADIMED CORP IRMD · Entity 4896 | PurchaseCommon Stock | 5,000 | $8.55 | $42,750.00 |
DisclosureSEC source: 0001140361-17-005881 · doc1.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, President, Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.